Welcome to our dedicated page for SS Innovations International news (Ticker: $SSII), a resource for investors and traders seeking the latest updates and insights on SS Innovations International stock.
SS Innovations International, Inc (SSII) was founded by a seasoned leadership team with vast experience in medical research, innovation, and development in the medical robotics sector. The company aims to meet the rising demand for practical medical robotic devices by creating a platform-independent precision guidance system, initially focusing on skin resurfacing.
The flagship SSi Mantra surgical device has been utilized in over 1000 procedures, showcasing the company's commitment to advancing robotic surgery. Dr. Sudhir Srivastava, the Chairman and CEO of SS Innovations, highlights the Mantra's fifth arm capability, enabling complex cardiac surgeries with minimal invasiveness, reduced blood loss, quicker recovery times, and superior outcomes.
The global market for cardiac surgery devices and surgical robotics is growing rapidly, presenting significant opportunities for SS Innovations. The Company's innovative approach and unique value proposition position it well for future success and market expansion.
Rhea-AI Summary
SS Innovations launches innovative robotic cardiac surgery program in India using the SSi Mantra surgical robotic system. Over 20 successful surgeries performed to date. Plans to expand internationally. Dr. Sudhir Srivastava performed world's first beating heart robotic cardiac bypass surgery. Mantra System granted regulatory approval in India, expects approvals in the US and Europe in 2024 and 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
-
Rhea-AI Summary
SS Innovations launches robotic cardiac surgery program in India, aiming to revive and invigorate the field of robotic coronary artery bypass and intracardiac surgery. More than 20 successful surgeries performed to date. Dr. Sudhir Srivastava performed world's first beating heart robotic cardiac bypass surgery using SSi Mantra. Plans to launch multiple programs in India and internationally. Expects regulatory approvals in the US and Europe in 2024 and 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
-
Rhea-AI Summary
SS Innovations International, Inc. has been featured on Indian national news for its work in the field of medical technology. The company aims to make robotic surgery affordable and accessible globally. They have developed the SSi Mantra, a surgical system made in India that is cost-effective and has broad-spectrum surgical applications. The system costs around a third of Intuitive Surgical's da Vinci device and has received regulatory approval in India. SS Innovations is working on securing regulatory approvals in the United States and Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
Rhea-AI Summary
SS Innovations International, Inc. has announced the first international sale of its surgical robotic system, the SSi Mantra, to Aster Hospital in Dubai, United Arab Emirates. The SSi Mantra is a cost-effective system with broad-spectrum surgical applications that has been granted regulatory approval in India. The company has also begun the process of filing for FDA and CE approval. The system offers multi-specialty use and costs a fraction of the world's best-selling surgical robot, making it more accessible to hospitals, physicians, and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
-
Rhea-AI Summary
SS Innovations International, Inc. has announced that it is applying for FDA and CE regulatory approval for its surgical robotic device, the SSi Mantra. The company has retained Elexes, a regulatory and quality compliance firm, to support the approval process. The SSi Mantra is the first surgical system made in India and has broad-spectrum surgical applications. Elexes is known for its expertise in approval and post-market compliance of medical devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
Rhea-AI Summary
SS Innovations International, Inc. announces the retention of Elexes to pursue regulatory approvals for its surgical robotic device, the SSi Mantra. The device is cost-effective and has broad-spectrum surgical applications, including cardiac surgery. Elexes is a regulatory and quality compliance firm with expertise in medical devices and pharmaceutical drugs. SS Innovations aims to achieve FDA and CE approvals in 2024 and 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
-
Rhea-AI Summary
SS Innovations International, Inc. has been invited to present at the Emerging Growth Conference on July 12, 2023. The conference will feature Dr. Sudhir Srivastava, CEO and Founder of SS Innovations, who will introduce the company's flagship SSI Mantra surgical robotic system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is SS Innovations International, Inc's core focus?
SS Innovations specializes in developing medical robotic devices with a focus on platform-independent precision guidance systems.
How many procedures have used SS Innovations' flagship device?
The SSi Mantra surgical device has been utilized in over 1000 procedures, showcasing its effectiveness and impact in robotic surgery.
What differentiates the SSi Mantra surgical device in the market?
The Mantra's innovative design features a fifth arm capability, enabling it to perform complex cardiac surgeries with minimal invasiveness, reduced blood loss, and better patient outcomes.
What market trends support SS Innovations' growth?
The global market for cardiac surgery devices and surgical robotics is growing rapidly, presenting significant opportunities for SS Innovations' innovative solutions.
Who is Dr. Sudhir Srivastava and what is his role at SS Innovations?
Dr. Sudhir Srivastava is the Chairman and CEO of SS Innovations, leading the company's strategic market expansion and transformation of robotic surgery practices.
What is the projected growth rate of the global surgical robotics market?
The global surgical robotics market is projected to reach $188.8 billion by 2032, growing at a CAGR of 9.1% from 2023 to 2032, indicating a significant growth opportunity for SS Innovations.
How does SS Innovations plan to enhance its market position?
SS Innovations aims to receive FDA approval in the US and CE Mark approval in Europe in early 2025, further solidifying its market position and accelerating its global adoption.
What recent milestone did SS Innovations achieve with the SSi Mantra device?
SS Innovations reached a milestone with the SSi Mantra device, highlighting the company's strategic market expansion, access enhancement, and transformation of robotic surgery practices.
What is SS Innovations' competitive advantage in the medical robotics field?
SS Innovations' competitive advantage lies in its advanced platform-independent precision guidance system and innovative approach to robotic surgery, offering precise execution, less trauma, and superior overall outcomes.
How does SS Innovations plan to uplist its common stock to a National Securities Exchange?
SS Innovations has selected BDO to facilitate the uplisting of its common stock to a National Securities Exchange, demonstrating the company's commitment to transparent financial practices and regulatory compliance.
SS Innovations International, Inc.
OTC:SSII
SSII Rankings
SSII Stock Data
597.59M
32.82M
80.45%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
United States of America
Orlando